|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:biologic_DMARDs_include
|
gptkb:rituximab
gptkb:tocilizumab
gptkb:etanercept
gptkb:infliximab
gptkb:abatacept
gptkb:adalimumab
|
|
gptkbp:compatibleWith
|
acute pain relief
|
|
gptkbp:contraindication
|
pregnancy (some DMARDs)
|
|
gptkbp:effect_onset
|
weeks to months
|
|
gptkbp:first-line_DMARD
|
gptkb:methotrexate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DMARDs
|
|
gptkbp:includes
|
gptkb:cyclosporine
gptkb:methotrexate
gptkb:leflunomide
gptkb:biologic_DMARDs
gptkb:sulfasalazine
gptkb:targeted_synthetic_DMARDs
azathioprine
hydroxychloroquine
|
|
gptkbp:introduced
|
20th century
|
|
gptkbp:mechanismOfAction
|
modulate immune system
reduce inflammation
slow disease progression
|
|
gptkbp:require_monitoring
|
liver function
renal function
blood counts
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
subcutaneous injection
|
|
gptkbp:sideEffect
|
immunosuppression
liver toxicity
bone marrow suppression
increased infection risk
|
|
gptkbp:standsFor
|
gptkb:Disease-Modifying_Antirheumatic_Drugs
|
|
gptkbp:subclassOf
|
gptkb:biologic_DMARDs
gptkb:conventional_synthetic_DMARDs
gptkb:targeted_synthetic_DMARDs
|
|
gptkbp:targeted_synthetic_DMARDs_include
|
gptkb:tofacitinib
gptkb:upadacitinib
gptkb:baricitinib
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:systemic_lupus_erythematosus
gptkb:psoriatic_arthritis
rheumatoid arthritis
ankylosing spondylitis
|
|
gptkbp:bfsParent
|
gptkb:psoriatic_arthritis
|
|
gptkbp:bfsLayer
|
6
|